Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia

被引:5
作者
Mostafa, Sam [1 ,2 ,15 ]
Rafizadeh, Reza [3 ]
Polasek, Thomas M. [1 ,4 ,5 ]
Bousman, Chad A. [6 ,7 ,8 ,9 ]
Rostami-Hodjegan, Amin [10 ,11 ]
Stowe, Robert [12 ,13 ,14 ]
Carrion, Prescilla [12 ]
Sheffield, Leslie J. [2 ]
Kirkpatrick, Carl M. J. [1 ]
机构
[1] Monash Univ, Ctr Med Use & Safety, Parkville, Vic, Australia
[2] MyDNA Life Australia Ltd, South Yarra, Vic, Australia
[3] BC Psychosis Program, BC Mental Hlth & Subst Use Serv, Lower Mainland Pharm Serv, Vancouver, BC, Canada
[4] Certara, Princeton, NJ USA
[5] Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA, Australia
[6] Univ Melbourne & Melbourne Hlth, Melbourne Neuropsychiat Ctr, Dept Psychiat, Melbourne, Vic, Australia
[7] Univ Calgary, Alberta Childrens Hosp Res Inst, Cumming Sch Med, Calgary, AB, Canada
[8] Univ Calgary, Hotchkiss Brain Inst, Cumming Sch Med, Calgary, AB, Canada
[9] Univ Calgary, Dept Med Genet Psychiat Physiol & Pharmacol, Calgary, AB, Canada
[10] Univ Manchester, Ctr Appl Pharmacokinet Res CAPKR, Sch Hlth Sci, Manchester, England
[11] Certara UK Ltd, Simcyp Div, Sheffield, England
[12] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
[13] Univ British Columbia, Djavid Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada
[14] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[15] Monash Univ, Ctr Med Use & Safety, 381 Royal Parade, Parkville, Vic 3052, Australia
关键词
VARIABILITY; PREDICTION;
D O I
10.1002/psp4.13093
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Model-informed precision dosing using virtual twins (MIPD-VTs) is an emerging strategy to predict target drug concentrations in clinical practice. Using a high virtualization MIPD-VT approach (Simcyp version 21), we predicted the steady-state clozapine concentration and clozapine dosage range to achieve a target concentration of 350 to 600 ng/mL in hospitalized patients with treatment-resistant schizophrenia (N = 11). We confirmed that high virtualization MIPD-VT can reasonably predict clozapine concentrations in individual patients with a coefficient of determination (R2) ranging between 0.29 and 0.60. Importantly, our approach predicted the final dosage range to achieve the desired target clozapine concentrations in 73% of patients. In two thirds of patients treated with fluvoxamine augmentation, steady-state clozapine concentrations were overpredicted two to four-fold. This work supports the application of a high virtualization MIPD-VT approach to inform the titration of clozapine doses in clinical practice. However, refinement is required to improve the prediction of pharmacokinetic drug-drug interactions, particularly with fluvoxamine augmentation.
引用
收藏
页码:424 / 436
页数:13
相关论文
共 22 条
[1]  
[Anonymous], Pharmacogene Variation Consortium PharmVar
[2]   International trends in clozapine use: a study in 17 countries [J].
Bachmann, C. J. ;
Aagaard, L. ;
Bernardo, M. ;
Brandt, L. ;
Cartabia, M. ;
Clavenna, A. ;
Coma Fuste, A. ;
Furu, K. ;
Garuoliene, K. ;
Hoffmann, F. ;
Hollingworth, S. ;
Huybrechts, K. F. ;
Kalverdijk, L. J. ;
Kawakami, K. ;
Kieler, H. ;
Kinoshita, T. ;
Lopez, S. C. ;
Machado-Alba, J. E. ;
Machado-Duque, M. E. ;
Mahesri, M. ;
Nishtala, P. S. ;
Piovani, D. ;
Reutfors, J. ;
Saastamoinen, L. K. ;
Sato, I. ;
Schuiling-Veninga, C. C. M. ;
Shyu, Y. -C. ;
Siskind, D. ;
Skurtveit, S. ;
Verdoux, H. ;
Wang, L. -J. ;
Yahni, C. Zara ;
Zoega, H. ;
Taylor, D. .
ACTA PSYCHIATRICA SCANDINAVICA, 2017, 136 (01) :37-51
[3]  
Clinical Pharmacogenetics Implementation Consortium (CPIC), US
[4]   Plasma Clozapine, Norclozapine, and the Clozapine: Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993-2007 [J].
Couchman, Lewis ;
Morgan, Phillip Edgar ;
Spencer, Edgar Pathrose ;
Flanagan, Robert James .
THERAPEUTIC DRUG MONITORING, 2010, 32 (04) :438-447
[5]   Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy [J].
Darwich, Adam S. ;
Polasek, Thomas M. ;
Aronson, Jeffrey K. ;
Ogungbenro, Kayode ;
Wright, Daniel F. B. ;
Achour, Brahim ;
Reny, Jean-Luc ;
Daali, Youssef ;
Eiermann, Birgit ;
Cook, Jack ;
Lesko, Lawrence ;
McLachlan, Andrew J. ;
Rostami-Hodjegan, Amin .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 :225-245
[6]  
de Leon J, 2022, PHARMACOPSYCHIATRY, V55, P73, DOI 10.1055/a-1625-6388
[7]   Data-driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment [J].
Fendt, Rebekka ;
Hofmann, Ute ;
Schneider, Annika R. P. ;
Schaeffeler, Elke ;
Burghaus, Rolf ;
Yilmaz, Ali ;
Blank, Lars Mathias ;
Kerb, Reinhold ;
Lippert, Joerg ;
Schlender, Jan-Frederik ;
Schwab, Matthias ;
Kuepfer, Lars .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (07) :782-793
[8]   Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity [J].
Gerhart, Jacqueline G. ;
Carreno, Fernando O. ;
Loop, Matthew Shane ;
Lee, Craig R. ;
Edginton, Andrea N. ;
Sinha, Jaydeep ;
Kumar, Karan R. ;
Kirkpatrick, Carl M. ;
Hornik, Christoph P. ;
Gonzalez, Daniel .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (02) :391-403
[9]  
Illumina, 2017, HISEQ X SYSTEM LAB S
[10]   The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis [J].
Koonrungsesomboon, Nut ;
Khatsri, Rapheephorn ;
Wongchompoo, Penwisa ;
Teekachunhatean, Supanimit .
PHARMACOGENOMICS JOURNAL, 2018, 18 (06) :760-768